Financial statements Lux Med Onkologia
Balance sheet data of LUX MED ONKOLOGIA
Year
|
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|---|---|---|---|---|---|
Total assets | 213 575,00 | 219 347 366,26 | 214 492 215,16 | 215 237 353,15 | 226 960 642,40 | 253 162 478,30 |
A. Fixed assets | 173 598,00 | 187 980 447,64 | 181 311 738,65 | 179 030 311,76 | 182 804 004,94 | 191 495 965,78 |
B. Current assets | 39 977,00 | 31 366 918,62 | 33 180 476,51 | 36 207 041,39 | 44 156 637,46 | 61 666 512,52 |
C. Share capital contributions (basic funds) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
D. Own shares (stocks) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
Total liabilities | 213 575,00 | 219 347 366,26 | 214 492 215,16 | 215 237 353,15 | 226 960 642,40 | 253 162 478,30 |
A. Equity | -51 140,00 | 39 540,63 | 30 311 899,24 | 31 161 983,97 | 40 397 239,55 | 55 153 787,55 |
B. Liabilities and provisions for liabilities | 264 715,00 | 219 307 825,63 | 184 180 315,92 | 184 075 369,18 | 186 563 402,85 | 198 008 690,75 |
I. Long-term liabilities | 226 831,00 | 188 322 392,85 | 148 248 613,83 | 146 719 613,75 | 145 085 041,97 | 143 347 451,40 |
II. Short-term liabilities | 35 028,00 | 28 450 140,10 | 31 630 007,21 | 31 864 367,92 | 35 672 335,58 | 42 045 667,10 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
- Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
- Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
- Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
- Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
- Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
- Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.